The efficacy biomarker of the currently licensed anthrax vaccine (AVA) is based on quantity and neutralizing capacity of anti-protective antigen (anti-PA) antibodies. However, animal studies have demonstrated that antibodies to lethal factor (LF) can provide protection against in vivo bacterial spore challenges. Improved understanding of the fine specificities of humoral immune responses that p...

We assess pre-outbreak and during-outbreak vaccination as control strategies for SARS epidemics using a mathematical model that includes susceptible, latent (traced and untraced), infectious, isolated and recovered individuals. Scenarios focusing on policies that include contact tracing and levels of self-isolation among untraced infected individuals are explored. Bounds on the proportion of pr...

Through years, the use of vaccines has always been a controversial issue. People in a society may have different opinions about how beneficial the vaccines are and as a consequence some of those individuals decide to vaccinate or not themselves and their relatives. This attitude in face of vaccines has clear consequences in the spread of diseases and their transformation in epidemics. Motivated...

DNA vaccines encoding the viral G glycoprotein show the most successful protection capability against fish rhabdoviruses. Nowadays, the molecular mechanisms underlying the protective response remain still poorly understood. With the aim of shedding light on the protection conferred by the DNA vaccines based in the G glycoprotein of viral haemorrhagic septicaemia virus (VHSV) in turbot (Scophtha...

bovine tropical theileriosis caused by theileria annulata is an economically important disease of cattle. an enzyme linked immunosorbent assay (elisa) was used to determine antibody levels in vaccinated and unvaccinated cattle, us¬ing cellular schizont as antigen and its results were compared with immunofluo-rescent assay (ifa). for this test 126 sera collected (105 vaccinated, 31 not vacci¬nat...

Vaccination against the coronavirus disease 2019 (COVID-19) started in early December of 2020 USA. The efficacy vaccines vary depending on SARS-CoV-2 variant. Some countries have been able to deploy strong vaccination programs, and large proportions their populations fully vaccinated. In other countries, low vaccinated, due different factors. For instance, such as Afghanistan, Cameroon, Ghana, ...

Vaccinia virus naturally circulates in Brazil and is the causative agent of a zoonotic disease known as bovine vaccinia (BV). We retrospectively evaluated two populations from the Amazon and Southeast Regions. BV outbreaks had not been reported in these regions before sample collection. Neutralising antibodies were found in 13 individuals (n = 132) with titres ranging from 100 ≥ 6,400 neutralis...

Abstract The BNT162b2 mRNA vaccine is highly effective against SARS-CoV-2. However, apprehension exists that variants of concern (VOCs) may evade protection, due to evidence reduced neutralization the VOCs B.1.1.7 and B.1.351 by sera in laboratory assays. We performed a matched cohort study examine distribution infections vaccinees from Clalit Health Services (Israel) using viral genomic sequen...

results before boosting, among 176 boosted individuals, 75 (42.6%) had hbsab 10 iu/l and were considered seroprotected. among 101 serosusceptible persons, more than 80% of boosted individuals showed more than twofold increase in cytokines concentration, which meant positive hbsag-specific cell-mediated immunity. mcl of both cytokines after boosting in giv were decreased more than twofold, possi...